The American Society of Clinical Oncology Consensus Conference recommended serum CEA level as a Class I prognostic indicator for CRC, highlighting the importance of measuring CEA levels in the prognostic assessment of patients with CRC. This evidence concerns the gene CEACAM5 and colorectal carcinoma.